Infectech, Inc. Approves Name Change to NanoLogix and Enters Hydrogen Production, BioDefense, Medical Diagnostics and Cancer Drug Markets

    SHARON, Pa., April 7 /PRNewswire-FirstCall/ -- Infectech, Inc.,
 (Pink Sheets:   IFEC), a Nanobiotechnology company engaged in the research,
 development and commercialization of technologies for the production of
 bacteria and disease testing kits, alternative sources of fuel, cancer therapy
 and remediation of toxic materials, announced today that the company has
 changed its name to NANOLOGIX, INC. The Company's name change was approved in
 a March 30 special meeting, during which a proposal to reverse split the
 company's common stock was turned down due to resistance from minority
 shareholders.
     The convergence of science, medicine and technology is on the cusp of
 yielding extraordinary breakthroughs.  Today, patents that were once designed
 to identify bacteria have widespread applications across multiple markets.  At
 the heart of this convergence is nature.  All things begin and end with the
 building blocks of life.  NanoLogix's portfolio of 31 patents have yielded a
 method vital to the development of nanotechnology products, a method for low
 cost hydrogen production, FDA registered products in the medical device
 industry, a genomic cancer therapy and methods for cleaning up toxic
 environments using bioremediation.  According to Lux Research, sales of
 products that incorporate nanotechnology are expected to explode over the next
 five years, from $12.98 billion in 2004 to an estimated $507.74 billion in
 2010. The following validates the value of NanoLogix's broad patent portfolio
 along with its current and future product lines.
     NanoLogix's patents have nanotechnology applications in hydrogen gas
 production, medical drugs/devices, bio-defense sensors and bioremediation.
 Nanotechnology applications include Biochips embedded in small transportable
 devices for rapid bacteria identification of disease causing pathogens, and
 Bio Micro Electro Mechanical Systems ("BioMEMS") for rapid environmental
 microbial monitoring with bio-defense implications. Its hydrogen bioreactor
 research is designed to assist in worldwide energy independence and reduce
 pollution using renewable, environmentally-friendly energy sources.
 NanoLogix's FDA registered diagnostic test kits are designed to be used for
 the rapid identification of infectious human diseases and identify 34 disease-
 producing bacteria, including Tuberculosis (TB), Mycobacterium avium-
 intracellulare (MAI), Pseudomonas, and Nocardia. These bacteria are cited as
 prominent causes of morbidity and mortality in patients with cancer, cystic
 fibrosis, and AIDS, as well as in patients undergoing surgery. Additionally,
 NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer
 cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a
 genetically based induction of "cell suicide" in cells. It therefore serves as
 the foundation for cancer therapy. NanoLogix's other patents include
 technology designed for use in the bioremediation of contaminated soil and
 water.
     For a detailed report on NanoLogix please
 visit:  http://www.biotechstocksignals.com/ifec.pdf
 
     Investment Highlights:
      -- FDA Registration of Identikits.  NanoLogix receives medical device
         exemption from FDA and can begin manufacturing and selling its
         biophasic system devices which detect Mycobacterium Tuberculosis (TB),
         Mycobacterium avium complex (MAC), Paratuberculosis, Pseudomonas,
         Nocardia and up to 34 different bacteria.
      -- The Indian Journal of Tuberculosis publishes Mahatma Gandhi Institute
         of medical Sciences research for isolation of Mycobacterium Avium
         Complex (MAC) using NanoLogix patented paraffin baiting technology.
      -- Ohio State University validates NanoLogix patented paraffin baiting
         technology.
      -- NanoLogix signs deal with Gannon University to build hydrogen
         bioreactor.
      -- NanoLogix in discussions with one of the largest juice company in U.S.
         to demonstrate feasibility of a pilot scale unit to convert millions
         of gallons of wastewater per year into hydrogen gas.
      -- The Royal Society of Chemistry publishes University of Cincinnati
         research for developing Biochips using NanoLogix patented paraffin
         baiting technology.
      -- National Science Foundation awards grant to University of Cincinnati
         for BioMEMS research using NanoLogix's patented paraffin baiting
         technology.
      -- NanoLogix granted patent for nontoxic genomics therapy for cancer.
      -- Journal of Laboratory Technology for Bioresearch (BioTechniques)
         publishes NanoLogix's research on cell death using hydrophobic
         hydrocarbons.
 
     About NanoLogix, Inc.
     NanoLogix, Inc., http://www.infectech.com , is a technology application
 innovator of biogas products and services designed to assist in worldwide
 energy independence and reduce pollution from renewable, environmentally-
 friendly energy sources. NanoLogix is also engaged in the research and
 development of diagnostic test kits designed to be used for the rapid
 identification of infectious human diseases. The Company's patents span the
 identification and antibiotic sensitivity testing of 34 disease-producing
 bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare
 (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes
 of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
 Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis
 in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for
 inducing a genetically based induction of "cell suicide" in cells. The
 Company's 31 patents can be viewed by
 visiting http://www.infectech.com/intellectual_property.php .
 
     This press release contains statements, which may constitute "forward-
 looking statements" within the meaning of the Securities Act of 1933 and the
 Securities Exchange Act of 1934, as amended by the Private Securities
 Litigation Reform Act of 1995. Those statements include statements regarding
 the intent, belief or current expectations of NanoLogix, Inc., and members of
 its management as well as the assumptions on which such statements are based.
 Prospective investors are cautioned that any such forward-looking statements
 are not guarantees of future performance and involve risks and uncertainties,
 and that actual results may differ materially from those contemplated by such
 forward-looking statements. Important factors currently known to management
 that could cause actual results to differ materially from those in forward-
 statements include fluctuation of operating results, the ability to compete
 successfully and the ability to complete before-mentioned transactions. The
 company undertakes no obligation to update or revise forward-looking
 statements to reflect changed assumptions, the occurrence of unanticipated
 events or changes to future operating results.
 
 

SOURCE Infectech, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.